June 16, 2020
Meiji Seika Pharma and Solasia Pharma plan to file their investigational cancer agent SP-02 (darinaparsin) in Japan for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in the first half of next year after positive PII data. The...read more